The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...
Discover why refining COAs is essential to capturing subtle, meaningful patient change—and how teams can close the ...
The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback